Neurocognitive Effects of Non-Invasive Near-Infrared Light Stimulation

Last updated: July 10, 2025
Sponsor: University of Texas at Austin
Overall Status: Active - Recruiting

Phase

N/A

Condition

Autism Spectrum Disorder (Asd)

Mild Cognitive Impairment

Attention Deficit/hyperactivity Disorder (Adhd - Adults)

Treatment

Transcranial photobiomodulation

Sham transcranial photobiomodulation

Clinical Study ID

NCT05802680
2019080005
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Inattentiveness and impulsivity in healthy adults and individuals with attention deficit hyperactivity disorder (ADHD) diminish these individuals' quality of life. Cortical hypometabolism has been hypothesized to contribute to inattentiveness in ADHD. Transcranial photobiomodulation (tPBM) is a safe and non-invasive modality for activation of the prefrontal cortex. tPBM in healthy adults has been shown to augment brain oxygenation, cognition, and mood. The cognition-enhancing effect of tPBM on sustained attention in adults with ADHD remains unstudied. The investigators will evaluate whether tPBM administration to adults with and without ADHD can improve their attention. Each participant will be screened for eighteen criteria based on the Diagnostic and Statistical Manual (DSM-IV, text revised), using the validated instrument Adult ADHD Self-Report Scale (ASRS-v1.1). Blinded participants will be randomized into (I) Active-tPBM or (II) Sham-tPBM groups. After undergoing an 8-minute administration of Sham or 1064 nm tPBM to the lateral and medial right prefrontal cortex, each participant will complete a 14-minute, computer-based Conner's continuous performance task-3 (CPT-3). The investigators will examine whether adults with and without ADHD who receive Active-tPBM improve in measures of inattention, impulsivity, sustained attention, or vigilance compared to the Sham-tPBM group. Cognitive assessments of attention like the CPT-3 may evaluate the efficacy of tPBM to increase cortical metabolism in healthy adults and individuals with conditions like ADHD. The investigators anticipate their investigation will be a starting point for more sophisticated studies that focus on the implications of tPBM on cognition.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • 18 years of age or older

Exclusion

Exclusion Criteria:

  • None

Study Design

Total Participants: 500
Treatment Group(s): 2
Primary Treatment: Transcranial photobiomodulation
Phase:
Study Start date:
February 09, 2022
Estimated Completion Date:
February 01, 2027

Connect with a study center

  • The University of Texas at Austin

    Austin, Texas 78712
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.